RECURSION PHARMACEUTICALS, INC. Interest Expense Nonoperating
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Interest Expense Nonoperating of $309.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-05
- RECURSION PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $309.00K, a 35.62% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $350.00K, a 31.10% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was -$11.00K, a 101.82% decline year-over-year.
- RECURSION PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $833.00K, a 50.63% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2025 was $1.81M, a 15.14% increase from fiscal 2024.
- RECURSION PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2024 was $1.57M, a 1520.62% increase from fiscal 2023.
- RECURSION PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2023 was $97.00K, a 76.36% increase from fiscal 2022.
- RECURSION PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2022 was $55.00K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $309.00K 10-Q · filed 2026-08-05 | $659.00K 10-Q · filed 2026-08-05 | $648.00K derived: sum of 3 quarters · filed 2026-08-05 | $1.48M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $350.00K 10-Q · filed 2026-05-06 | $339.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.17M derived: sum of 3 quarters · filed 2026-05-06 | $1.65M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $822.00K derived: sum of 2 quarters · filed 2026-02-25 | $1.30M derived: sum of 3 quarters · filed 2026-08-05 | $1.81M 10-K · filed 2026-02-25 |
| 2025-09-30 | $833.00K 10-Q · filed 2025-11-05 | $1.31M derived: sum of 2 quarters · filed 2026-08-05 | $1.82M 10-Q · filed 2025-11-05 | $2.43M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $480.00K 10-Q · filed 2026-08-05 | $988.00K 10-Q · filed 2026-08-05 | $1.59M derived: sum of 3 quarters · filed 2026-08-05 | $2.15M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $508.00K 10-Q · filed 2026-05-06 | $1.11M derived: sum of 2 quarters · filed 2026-05-06 | $1.67M derived: sum of 3 quarters · filed 2026-05-06 | $2.06M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $605.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $1.16M derived: sum of 2 quarters · filed 2026-02-25 | $1.55M derived: sum of 3 quarters · filed 2026-02-25 | $1.57M 10-K · filed 2026-02-25 |
| 2024-09-30 | $553.00K 10-Q · filed 2025-11-05 | $947.00K derived: sum of 2 quarters · filed 2025-11-05 | $967.00K 10-Q · filed 2025-11-05 | $993.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $394.00K 10-Q · filed 2025-08-05 | $414.00K 10-Q · filed 2025-08-05 | $440.00K derived: sum of 3 quarters · filed 2026-02-25 | $465.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $20.00K 10-Q · filed 2025-05-05 | $46.00K derived: sum of 2 quarters · filed 2026-02-25 | $71.00K derived: sum of 3 quarters · filed 2026-02-25 | $97.00K derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $51.00K derived: sum of 2 quarters · filed 2026-02-25 | $77.00K derived: sum of 3 quarters · filed 2026-02-25 | $97.00K 10-K · filed 2026-02-25 |
| 2023-09-30 | $25.00K 10-Q · filed 2024-11-06 | $51.00K derived: sum of 2 quarters · filed 2024-11-06 | $71.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $26.00K 10-Q · filed 2024-08-08 | $45.00K 10-Q · filed 2024-08-08 | ||
| 2022-12-31 | $55.00K 10-K · filed 2025-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |